NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $0.96 -0.03 (-3.05%) (As of 01:50 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About NeuroSense Therapeutics Stock (NASDAQ:NRSN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NRSN alerts:Sign Up Key Stats Today's Range$0.91▼$1.0250-Day Range$0.96▼$1.3552-Week Range$0.51▼$2.33Volume81,734 shsAverage Volume257,778 shsMarket Capitalization$13.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! NeuroSense Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks13th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 13% of companies evaluated by MarketBeat, and ranked 910th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NeuroSense Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.63% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently increased by 62.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.63% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently increased by 62.49%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News SentimentN/A News SentimentNeuroSense Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NeuroSense Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRSN Stock News HeadlinesNeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDNovember 21 at 9:20 AM | prnewswire.comNeuroSense Therapeutics Secures Continued Nasdaq ListingNovember 13, 2024 | markets.businessinsider.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)NeuroSense Completes Key ALS Trial PhaseNovember 1, 2024 | markets.businessinsider.comNeurosense Therapeutics Secures $30 Million Equity DealNovember 1, 2024 | markets.businessinsider.comNeuroSense Therapeutics Advances ALS Drug Development PlansOctober 29, 2024 | markets.businessinsider.comEXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application SubmissionOctober 28, 2024 | msn.comNeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionOctober 28, 2024 | prnewswire.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of 2024. Since then, NRSN shares have increased by 22.3% and is now trading at $0.9603. View the best growth stocks for 2024 here. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. Who are NeuroSense Therapeutics' major shareholders? Top institutional shareholders of NeuroSense Therapeutics include XTX Topco Ltd (0.34%). How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Today11/21/2024Next Earnings (Estimated)11/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRSN CUSIPN/A CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-286.31% Debt Debt-to-Equity RatioN/A Current Ratio0.46 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-7.07Miscellaneous Outstanding Shares13,670,000Free Float9,922,000Market Cap$13.53 million OptionableNot Optionable Beta1.58 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NRSN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.